Spotlight: Maria Artunduaga, MD, MPH, MTM, Ferolyn Fellow

When her beloved grandmother died from chronic obstructive pulmonary disease (COPD), a progressive lung condition that obstructs breathing, Maria Artunduaga, MD, MPH, MTM, realized it was an area that needed attention. That incident became a turning point in her training, leading her to the next phase of what has already been a highly accomplished career.

Q&A with Deborah Kilpatrick, Ph.D., CEO of Evidation Health; Ferolyn Fellowship Advisory Board Member

If you want a snapshot of Deborah (Deb) Kilpatrick’s storied career, you need look no further than the numerous accolades she has amassed. As just a sampling, she has been named on lists such as MM&M’s Top 40 Healthcare Transformers, FierceMedicalDevices’ Top Women in Medical Devices, Business Insider’s Most Powerful Women Engineers,

iDentical Gives Patients and Dentists Something To Smile About With Drill-Free Dental Implants That are Lower Cost and More Accessible

Thanks to improved tooth-brushing habits, regular dental care and ubiquitous fluoridation, most Americans have benefited from better tooth health. And yet, many still lose their teeth, whether due to injury, decay or periodontal disease. In fact, studies find that approximately 178 million people in the United States are missing at least one tooth, and a surprising 40 million are missing all their teeth.

Panel Agrees IP Is Key To Earn Interest From VCs

Few seminar topics engage a startup audience as wholly as intellectual property, given that it’s viewed as one of the most critical components to success. Not only does it protect a company and allow it to compete among larger players, but it raises a startup’s profile among investors. In fact, 85 percent of medical device VCs say they view patents as a critical factor for funding consideration.

Q&A with Casey McGlynn, Partner at Wilson Sonsini Goodrich & Rosati; Fogarty Institute Board Member

Training the next generation of medtech leaders is a topic of vital importance to the Fogarty Institute, given all our efforts in that direction. That’s why Andrew Cleeland was honored to be interviewed on that topic, along with Paul Yock, co-founder and director of the Stanford Biodesign program, at the opening dinner of the Wilson Sonsini Goodrich &

Chronus Health, FII’s Newest Company, Poised to Revolutionize $80 Billion U.S. Clinical Laboratory Testing Market

Imagine going to the doctor’s office for your annual check-up. The nurse starts going through the usual tests, such as measuring your blood pressure, heart rate and temperature and completing the blood draw from your arm.

Then the nurse immediately starts testing your blood with a hand-held device, explaining that instead of waiting for the sample to return from the lab,

START TYPING AND PRESS ENTER TO SEARCH